Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + everolimus in recurrent or refractory pediatric solid tumors
2022-003736-77Phase 2
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib and everolimus in Nonhematologic neoplasms, central nervous system tumor, Ewing sarcoma and 2 more (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum tolerated dose of lenvatinib in combination with everolimus and Recommended Phase 2 dose.
02
Drugs
lenvatinibeverolimus
03
Conditions
Nonhematologic neoplasmscentral nervous system tumorEwing sarcomarhabdomyosarcoma (RMS)glioma
Beyond the preview
Go deeper on 2022-003736-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003736-77.